Joseph L. Pater

Joseph L. Pater's AcademicInfluence.com Rankings

Joseph L. Pater

Philosophy

#9354

World Rank

#12901

Historical Rank

Logic

#6335

World Rank

#7846

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Joseph L. Pater's Degrees

Doctorate Medicine Stanford University

Why Is Joseph L. Pater Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joseph L. Pater's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Interpreting the significance of changes in health-related quality-of-life scores. (1998) (2510)
Erlotinib in lung cancer - molecular and clinical predictors of outcome. (2005) (1488)
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial (2002) (1145)
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
Quality of life and pharmacoeconomics in clinical trials (1996) (993)
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. (1998) (978)
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) (882)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. (1988) (728)
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. (1993) (667)
Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. (2005) (561)
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. (2003) (538)
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis (1993) (501)
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. (1998) (469)
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. (1996) (446)
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis (2008) (349)
Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer (1994) (321)
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? (2003) (308)
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. (1996) (297)
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. (2005) (260)
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. (2005) (243)
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. (2002) (242)
Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy (2004) (222)
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. (1998) (212)
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. (1997) (211)
Effect of postchemotherapy nausea and vomiting on health-related quality of life (1997) (209)
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. (1990) (205)
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. (2010) (199)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Effect of daily etidronate on the osteolysis of multiple myeloma. (1991) (185)
Assessing quality of life in clinical trials. (1993) (183)
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
Letters to the editor: Assessing quality of life in clinical trials (1993) (172)
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). (2002) (158)
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. (1997) (150)
Influence of age on the treatment of limited-stage small-cell lung cancer. (1996) (143)
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. (2008) (133)
A validation study of the domains of the core EORTC Quality of Life Questionnaire (1993) (131)
Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. (1987) (129)
Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. (1993) (127)
Communicating quality of life information to cancer patients: a study of six presentation formats. (2005) (124)
Priority-setting decisions for new cancer drugs: a qualitative case study (2001) (121)
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. (1998) (112)
Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. (1983) (105)
Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. (1995) (104)
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. (1997) (102)
The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. (1999) (96)
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. (2004) (90)
Nonanatomic prognostic factors in carcinoma of the lung. A multivariate analysis (1982) (89)
Carryover and the two-period crossover clinical trial. (1986) (88)
The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial. (1988) (85)
Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. (1988) (85)
Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. (2000) (84)
Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30 (1997) (82)
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. (1998) (81)
Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. (2004) (74)
Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. (2002) (73)
Comparison of Mouth Guard Designs and Concussion Prevention in Contact Sports: A Multicenter Randomized Controlled Trial (2005) (71)
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. (1991) (71)
Quality of life studies in chemotherapy-induced emesis. (1996) (70)
Quality-of-Life Assessment: Patient Compliance With Questionaire Completion (1992) (65)
Quinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Patients: Effect of Augmented Gram-Positive Activity on Infectious Morbidity (1996) (64)
A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. (2006) (64)
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. (1997) (63)
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
Reliability of the time trade-off technique of utility assessment in patients with retinal disease. (2001) (61)
Research on health-related quality of life: dissemination into practical applications (1994) (57)
Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. (2002) (56)
Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. (2006) (56)
Cancer patients' preferences for communicating clinical trial quality of life information: A qualitative study (2003) (56)
A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. (1992) (55)
Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG). (2000) (55)
Systemic Infusion Versus Bolus Chemotherapy with 5‐Fluorouracil in Measurable Metastatic Colorectal Cancer (1992) (52)
Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. (1991) (51)
Adjustment of Treatment Effect for Covariates in Clinical Trials: Statistical and Regulatory Issues (2000) (47)
Does a visible retinal embolus increase the likelihood of hemodynamically significant carotid artery stenosis in patients with acute retinal arterial occlusion? (1998) (47)
Observer variation in the classification of information from medical records. (1979) (45)
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). (2006) (43)
Quality-of-life assessment: patient compliance with questionnaire completion. (1991) (41)
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. (1993) (41)
Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. (2007) (39)
Bilateral Massive Adrenal Hemorrhage: Assessment of Putative Risk Factors by the Case-Control Method (2001) (38)
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women (2011) (38)
Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. (2007) (38)
Comparing the predictive value of neural network models to logistic regression models on the risk of death for small-cell lung cancer patients. (2006) (37)
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. (1986) (36)
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. (2014) (36)
A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. (1992) (35)
Survival after recurrence of breast cancer. (1981) (35)
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. (1998) (35)
A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. (1985) (34)
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting (1994) (33)
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. (2006) (32)
Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. (1998) (32)
Effects of Altering the Time of Administration and the Time Frame of Quality of life Assessments in Clinical Trials: An Example Using the EORTC QLQ-C30 in a Large Anti-Emetic Trial (1998) (32)
Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. (1987) (31)
An empirical approach to informed consent in ovarian cancer. (1996) (30)
Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19 (2006) (30)
Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial. (1982) (30)
Treatment of locally advanced breast cancer (2004) (29)
Modified adriamycin‐vincristine‐dexamethasone (m‐VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study (1992) (28)
Methodologic issues in trials of antiemetics. (1984) (28)
The impact of registration of clinical trials units: The UK experience (2015) (27)
Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. (2006) (26)
A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. (2007) (25)
Using baseline measurements in the two-period crossover clinical trial. (1986) (25)
Can different types of retinal emboli be reliably differentiated from one another? An inter- and intraobserver agreement study. (1998) (25)
NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. (2006) (25)
Modeling toxicity and response in carboplatin-based combination chemotherapy. (1994) (25)
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. (1994) (24)
Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients--a critical survey. (1986) (23)
Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion. (1980) (22)
Anticipatory nausea and/or vomiting. (1984) (22)
Trimetrexate: predictors of severe or life-threatening toxic effects. (1988) (22)
Do patients with obstructive sleep apnea have clinically significant proteinuria? (2001) (19)
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. (2015) (19)
Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. (2001) (18)
Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. (2004) (18)
Randomized study of single versus fractionated radiotherapy (RT) in the palliation of non-small cell lung cancer; NCIC CTG SC.15 (2001) (18)
Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. (2016) (18)
Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. (1996) (18)
Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. (1994) (17)
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. (2008) (17)
Methods of toxicity data collection: An evaluation of the relative effectiveness of the case report flow sheet (FS), the patient symptom diary (SD), and the quality of life questionnaire (QLQ) (1991) (17)
A multivariate analysis of the contribution of "auxometry" to prognosis in breast cancer. (1979) (17)
Extent and Variation of Omeprazole Prescribing in an Elderly Population of Ontario (1997) (16)
Stopping a trial early in oncology: for patients or for industry? (2008) (15)
Phase II study of acivicin in non-small cell lung cancer: a National Cancer Institute of Canada Study. (1986) (15)
The economic impact of the transition from branded to generic oncology drugs. (2016) (14)
The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. (1988) (13)
Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. (1986) (13)
Polychemotherapy in advanced non-small-cell lung cancer. (1993) (13)
Sentinel lymph node biopsy in early breast cancer: has its time come? (2006) (12)
P31 Salvaging clinical trials forced to terminate early by results of external information (1993) (12)
Linkage of clinical trial and administrative data: a survey of cancer patient preferences. (2017) (12)
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. (2020) (12)
Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) perspective. (1994) (11)
Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward. (2003) (11)
Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs. (2002) (11)
Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee. (1992) (10)
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. (1991) (10)
The ethics of early stopping rules. (2005) (10)
The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer (2005) (9)
Recursive structural model: An approach to analyze data with treatment adherence problem in randomized clinical trials (1991) (8)
The restaging of responding patients with limited small cell lung cancer. Is it really useful? (1993) (8)
Simultaneous randomization to multiple dose levels and an active comparator as a means of determining the minimal effective dose of an investigational agent (1991) (8)
Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example (2008) (8)
Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. (1985) (8)
Optimal chemotherapy for women with breast cancer: the plot thickens. (2003) (8)
Clinical trials as diagnostic tests. (1984) (8)
Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study. (1984) (8)
The role of palliative radiotherapy for brain metastases. (1996) (7)
Health-related quality of life: measurement and clinical application. A workshop report. (1995) (7)
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial (2019) (7)
Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy (1993) (7)
P08 Numbers of events needed in comparing survival data to a standard population using the subjects-years method (1997) (7)
Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC). (2004) (6)
Priority-setting decisions for new cancer drugs (2002) (6)
Common toxicity criteria: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) experience (1992) (6)
1204 Preventing nausea and vomiting during days 2–7 following high dose cisplatin chemotherapy (HDCP) (1995) (6)
Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCIC CTG BR.21 trial (2005) (6)
Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses? (2019) (6)
Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes (2018) (5)
Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen (2005) (5)
Future research and methodological approaches. (2011) (5)
Stopping trials for benefit can (sometimes) benefit patients. (2008) (4)
A phase II study of menogaril in low-grade non-Hodgkin's lymphoma (1991) (4)
Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC) (2004) (4)
Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy. (1988) (4)
Canadian multicentre randomized trial comparing two dose levels of thoracic radiation given in combination with chemotherapy to patients with limited small cell lung cancer (1986) (4)
Correlations between target scores and anchor ratings on a health transition questionnaire (2002) (4)
Studies of human natural killer cells. III. Neutropenia associated with unusual characteristics of antibody-dependent and natural killer cell-mediated cytotoxicity (1982) (4)
Identifying patients with non-small cell lung cancer (NSCLC) unlikely to benefit from erlotinib: An exploratory analysis of National Cancer of Institute of Canada Clinical Trials Group BR.21. (2006) (4)
Assessment of palliation in patients with lung cancer: Comparisons between patient symptom diary scores and “minimum clinical change” in quality-of-life scores (2002) (4)
Clinical benefit in patients with cancer of the pancreas: How does it compare with clinically significant changes in quality-of-life scores? (2002) (4)
Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG). (2014) (3)
The use of data monitoring committees in Canadian trial groups. (1993) (3)
Variable effects of post-operative radiotherapy on disease-free survival in subgroups of patients with node-negative breast carcinoma. (1980) (3)
A proposal for a new approach to intergroup cancer trials. (1995) (3)
234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study (1997) (3)
NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women. (2006) (3)
Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer (1990) (3)
Bayesian Approaches to Randomized Trails - Discusion (1994) (2)
Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group. (2022) (2)
Improvement in survival after recurrence of carcinoma of the breast. (1983) (2)
233 The influence of age on the efficacy and tolerability of combined modality therapy in limited small cell lung cancer (L-SCLC) (1997) (2)
Does central monitoring of the timeless of forms result in a decrease in the quality of data (1991) (2)
Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD (2016) (2)
Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience. (2014) (2)
Does participation on concurrent clinical trials compromise the quality of the data or its timely submission (1991) (2)
Early closure of clinical trials: The experience of the National Cancer Institute of Canada Clinical Trials Group. (2006) (2)
Discussion: M K B Parmar and David Machin, monitoring clinical trials; Experience of, and proposals under consideration by the Cancer Therapy Committee of the British Medical Research Council (1993) (1)
Abstract P3-09-02: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG) (2015) (1)
A controlled trial of plasma exchange in rheumatoid arthritis (1984) (1)
Use of placebo in cancer medicine: The experience of a National Clinical Trials organization. (2006) (1)
A phase III study of the efficacy of dexamethasone (DEX) in the prophylaxis of radiation induced emesis (RIE) (1998) (1)
Industry involvement in cooperative oncology group studies. Results of a survey of study nurses/institutional data managers (1992) (1)
Patient preferences for research access to administrative data in Ontario. (2016) (1)
O-248 How should palliation be measured — illustrative examples from the NCIC CTG palliative thoracic radiation trial (2003) (1)
Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). (2015) (1)
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial (2019) (1)
A computer simulation study of methods of accounting for prognostic factors in clinical trials (1980) (1)
Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial (2017) (1)
Duration projection for equivalence clinical trials with survival endpoints (1998) (1)
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data (2021) (1)
Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. (2014) (0)
Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial (2016) (0)
Impact of Canadian Cancer Trials Group (CCTG) phase III trials (P3Ts). (2018) (0)
Contents, Supplement 1, 1996 (1996) (0)
Prospective linkage of clinical trial and administrative databases: Acceptability to patients and research ethics boards. (2018) (0)
Abstract Seventeenth annual meeting of the society for clinical trialP74 Quality of life (QL) as an outcome measure in the assessment of nausea (N) and vomiting (V) (1996) (0)
IIIB.1 Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup JBR.10 (2006) (0)
Optimal thoracic irradiation (TI) in the treatment of limited stage small cell lung cancer (LSCLC) (1991) (0)
Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada. (2014) (0)
The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-TKIs): A pooled analysis of NCIC Clinical Trial Group (NCIC CTG) trials. (2014) (0)
The paradox of rapid accrual (1992) (0)
Funding N ew C ancer D rugs i n O ntario: C losing t he L oop in t he P ractice G uidelines D evelopment C ycle (2001) (0)
·P-57 Sample size for trials where survival depends on first response rates (1990) (0)
Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6 (2023) (0)
Ethics and industry-sponsored research. (2002) (0)
TREATMENT EFFECT IN CLINICAL TRIALS: REGULATORY ISSUES (2000) (0)
Reporting of toxicity data in prospective clinical trials: Current patterns of practice and implications for analysis (1991) (0)
P75 Survey to evaluate case report forms for national multi-center clinical trials designed using genetic forms module (1995) (0)
Application of Value Frameworks to the Design of Clinical Trials: the Canadian Cancer Trials Group Experience. (2021) (0)
Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis. (1992) (0)
An Evaluation of Linked Administrative Data for Cancer Clinical Trial Economic Analysis (2020) (0)
790 Gender specific differences baseline of quality of life (QL) assessments in lung cancer patients: results from four National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) studies (1997) (0)
Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials (2021) (0)
Quality assurance and multicenter clinical trials (1992) (0)
[Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study]. (2001) (0)
In response to Dr.Lee (1995) (0)
Gender and age influence baseline quality of life (QL) assessments in cancer patients (1997) (0)
NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting (2008) (0)
A value framework analysis of the Canadian Cancer Trials Group. (2018) (0)
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen (2007) (0)
A62 Issues in implementing a multi-centre, placebo controlled sequential design trialof anti-emetic prophylaxis (AEP)inpatients (pts) receiving radiotherapy (R) (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joseph L. Pater?

Joseph L. Pater is affiliated with the following schools:

McMaster University
Queen's University at Kingston
University of Toronto